Alnylam

Alnylam is a biopharmaceutical company that develops and commercializes RNA interference (RNAi) therapeutics for various diseases, including cardiovascular and genetic conditions.

Why it’s in the news: It is in the news due to the high-profile failure of a closely watched heart disease drug and its subsequent partnership to develop AI models for RNAi therapeutics.

Latest on Alnylam

• STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
• STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
• STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conference
• STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics

Connections

4 entities linked to Alnylam across the news graph.